TY - JOUR
T1 - Assessment of FIBROSpect II to Detect Hepatic Fibrosis in Chronic Hepatitis C Patients
AU - Zaman, Atif
AU - Rosen, Hugo R.
AU - Ingram, Ken
AU - Corless, Christopher L.
AU - Oh, Esther
AU - Smith, Katie
N1 - Funding Information:
Funding for this study was given by Prometheus Laboratories, which included only the cost of serum fibrosis testing, shipping and handling costs, and statistical support. No other financial support was given.
PY - 2007/3
Y1 - 2007/3
N2 - Background: The degree of liver fibrosis in patients with Hepatitis C (HCV) provides important prognostic information; however, the only current method available to obtain this information is by performing a liver biopsy. Liver biopsies are invasive, associated with complications, and costly. There has been recent interest in developing a panel of serum markers that can reliably predict the presence of fibrosis and, thus, obviate the need for a liver biopsy. Our objective was to prospectively validate a panel of serum fibrosis markers (FIBROSpectSM II) that has been recently developed. Methods: Serum was obtained from 108 consecutive HCV (15% with HCV/ETOH) patients seen in a hepatology clinic at a single tertiary care center at the time of liver biopsy. The performance of FIBROSpect II (consisting of 3 fibrosis markers: hyaluronic acid, tissue inhibitor of metalloproteinases 1, and alpha-2-macroglobulin) in differentiating mild (F0-F1) from significant (F2-F4) fibrosis was assessed by comparing the panel results with performed liver biopsy. Results: The prevalence of significant fibrosis in the study group was 36.1%. The diagnostic value of the serum marker panel to detect significant fibrosis as assessed by area under the receiver operating characteristic (ROC) curve was 0.826. Performance characteristics are as follows: sensitivity 71.8%, specificity 73.9%, positive predictive value 60.9%, negative predictive value 82.3%, and overall accuracy of 73.1%. Conclusion: This prospective study supports the clinical utility of serum markers in detecting fibrosis and validates the performance of FIBROSpect II in a prospective cohort of patients. The high negative predictive value of the test provides a reliable alternative to rule out severe fibrosis.
AB - Background: The degree of liver fibrosis in patients with Hepatitis C (HCV) provides important prognostic information; however, the only current method available to obtain this information is by performing a liver biopsy. Liver biopsies are invasive, associated with complications, and costly. There has been recent interest in developing a panel of serum markers that can reliably predict the presence of fibrosis and, thus, obviate the need for a liver biopsy. Our objective was to prospectively validate a panel of serum fibrosis markers (FIBROSpectSM II) that has been recently developed. Methods: Serum was obtained from 108 consecutive HCV (15% with HCV/ETOH) patients seen in a hepatology clinic at a single tertiary care center at the time of liver biopsy. The performance of FIBROSpect II (consisting of 3 fibrosis markers: hyaluronic acid, tissue inhibitor of metalloproteinases 1, and alpha-2-macroglobulin) in differentiating mild (F0-F1) from significant (F2-F4) fibrosis was assessed by comparing the panel results with performed liver biopsy. Results: The prevalence of significant fibrosis in the study group was 36.1%. The diagnostic value of the serum marker panel to detect significant fibrosis as assessed by area under the receiver operating characteristic (ROC) curve was 0.826. Performance characteristics are as follows: sensitivity 71.8%, specificity 73.9%, positive predictive value 60.9%, negative predictive value 82.3%, and overall accuracy of 73.1%. Conclusion: This prospective study supports the clinical utility of serum markers in detecting fibrosis and validates the performance of FIBROSpect II in a prospective cohort of patients. The high negative predictive value of the test provides a reliable alternative to rule out severe fibrosis.
KW - Hepatic fibrosis
KW - Hepatitis C
UR - http://www.scopus.com/inward/record.url?scp=33847354646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847354646&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2006.06.044
DO - 10.1016/j.amjmed.2006.06.044
M3 - Article
C2 - 17349453
AN - SCOPUS:33847354646
SN - 0002-9343
VL - 120
SP - 280.e9-280.e14
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 3
ER -